Does Empagliflozin Linagliptin Metformin Hydrochloride Interact with Dichlorphenamide?
CDI records a major classification for Empagliflozin Linagliptin Metformin Hydrochloride and Dichlorphenamide. The stored summary is: Dichlorphenamide causes decreased serum bicarbonate and metabolic acidosis; concomitant use with TRIJARDY XR may increase risk of lactic acidosis. The mechanism involves carbonic anhydrase inhibition leading to metabolic acidosis. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Empagliflozin Linagliptin Metformin Hydrochloride Class
- Dipeptidyl Peptidase 4 Inhibitor
- Dichlorphenamide Class
- Carbonic Anhydrase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Carbonic anhydrase inhibition leading to metabolic acidosis
What To Tell Your Doctor or Pharmacist
If you are taking Empagliflozin Linagliptin Metformin Hydrochloride and your doctor is considering prescribing Dichlorphenamide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider